Literature DB >> 8466870

Cystic fibrosis and portal hypertension interest of partial splenectomy.

D Louis1, J P Chazalette.   

Abstract

Extra pulmonary complications can be major in patients suffering of cystic fibrosis who survive long enough without pulmonary problems. Hepatic cirrhosis is often present and is responsible for portal hypertension with splenomegaly, hypersplenism and esophageal varices. In six patients we have performed a partial splenectomy with conservation of the upper pole of the spleen vascularized by gastrosplenic omentum and its vessels. The post-operative complications (3 scar ruptures but no pulmonary decompensation) are not very important considering the benefits: Normal spleen according to clinical, ultrasonic examination and scintigraphy Correction of hypersplenism Diminution of esophageal varices Stability of hepatic functions. With a post-operative follow-up between 2.5 and 7 years, none of the patients had an increased risk of infection. This technique allows a good survival for those patients waiting for pulmonary transplantation.

Entities:  

Mesh:

Year:  1993        PMID: 8466870     DOI: 10.1055/s-2008-1063501

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  4 in total

1.  Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series.

Authors:  B Linnane; M R Oliver; P J Robinson
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

2.  Liver cirrhosis in cystic fibrosis.

Authors:  M D Stringer; J F Price; A P Mowat; E R Howard
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

3.  Partial splenectomy in cystic fibrosis patients with hypersplenism.

Authors:  G H Thalhammer; E Eber; S Uranüs; J Pfeifer; M S Zach
Journal:  Arch Dis Child       Date:  2003-02       Impact factor: 3.791

4.  Effects of splenohepatopexy and omentopexy in experimentally induced infrahepatic portal hypertension in rats.

Authors:  Dilek Polat; Riza Rizalar; Burak Tander; Levent Yildiz; Ender Aritürk; Ferit Bernay
Journal:  Pediatr Surg Int       Date:  2004-04-20       Impact factor: 1.827

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.